Office: 637 Salk Hall

Phone: 412-648-3012

Email: inh3@pitt.edu

URL: orcid.org/0000-0002-0118-4986

LinkedIn

Dr. Hernandez earned her PharmD from the University of Navarra (Spain) in 2013, and she completed her clinical training in the North Middlesex University Hospital and Green Light Pharmacy, both in London (UK). Hernandez was awarded her PhD in Health Services Research and Policy from the University of Pittsburgh Graduate School of Public Health in 2016, with a concentration in Quantitative Methods. Her doctoral dissertation focused on the real-world safety, effectiveness and cost-effectiveness of non-vitamin K antagonist oral anticoagulants. Hernandez was appointed Assistant Professor at the University of Pittsburgh School of Pharmacy in August 2016, at the age of 25. In Pitt Pharmacy, she will expand her pharmacoepidemiology and pharmacoeconomics research. Specifically, Hernandez is interested in the use of large data sets and advanced data mining techniques to study pharmaceutical outcomes. With regard to policy, Hernandez is interested in value-based health insurance design and the study of patterns of use of treatments with high evidence versus low evidence.

Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of Bleeding with Dabigatran in Atrial Fibrillation. JAMA Intern Med. 2015; 175(1):18-24.
Hernandez I, Zhang Y. Risk of Bleeding with Dabigatran in 2010-2011 Medicare Data. JAMA Intern Med. 2015; 175(7):1245-7
Hernandez I, Zhang Y. Comparing Clinical and Economic Outcomes of Biologic and Conventional Medications in Postmenopausal Women with Osteoporosis. J Eval Clin Pract. 2015; 21(5):840-7
Hernandez I. Time to Reconsider Dabigatran 110 mg in the US. Am J Cardiovasc Drug. 2015; 15(5):307-9
Hernandez I, Piñera A. Incidence of Fracture Events with Teriparatide: Role of Study Design. Osteoporosis Int. 2015; 28(6):2219.
Baik SH, Hernandez I, Zhang Y. Evaluating the Choice of Novel Oral Anticoagulants in Medicare. J Manag Care Spec Pharm. 2016; 22(3):281-82.
Hernandez, I. Risk Factors for Cardiovascular Events of Anti-dementia Drugs in Alzheimer’s disease patients. J Clin Gerontol Geriatr 2016; 7(3):77-82.
Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drug. doi:10.1007/s40256-016-0189-9
Hernandez I, Smith K, Zhang Y. Cost-Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation at High Risk of Bleeding and Normal Kidney Function. Thromb Res. doi: 10.1016/j.thromres.2016.10.006
Hernandez I, Zhang Y, Brooks M, Chin P, Saba S. Anticoagulation Use and Clinical Outcomes Following Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation. Stroke. doi: 10.1161/STROKEAHA.116.015150
Zhang Y, Hueser H, Hernandez I. International Variations in the Approval and Coverage Decision of New Oncology Drugs Approved Between 2009 and 2013. J Manag Care Spec Pharm. In press.
Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of Bleeding with Dabigatran in Atrial Fibrillation. JAMA Intern Med. 2015; 175(1):18-24.

1.“La Caixa” Foundation Fellowship 2013 (1 in 48 selected in Spain in 2013 to receive full tuition and stipend support to pursue Graduate Studies in North America).
2. Excellence Award First of the Pharmacy Class 2013 (University of Navarra).
3. American Heart Association 2016 Fellows Research Day 1st Place Award (Clinical Science Category).
4. PCORI/AHA Challenge Comparative Effectiveness Research and Precision Medicine Approaches for Heart Disease and Stroke Treatment Research and Clinician Challenge Award